Axatilimab is a colony-stimulating factor-1 receptor–blocking monoclonal antibody indicated after 2 lines of systemic therapy.
Grashma Vadakkel, PharmD, BCOP
Advertisement
Articles by Grashma Vadakkel, PharmD, BCOP
Treatment selection includes patient factors, cost, adverse effects, and drug interactions.
Treatment often involves a combination of preventive measures, topical therapies, and systemic treatments.
Current guidelines recommend a backbone of SLGT2 therapy in patients with HFpEF who have no contraindications.
Advertisement
Latest Updated Articles
New Therapy for Chronic Graft-Vs-Host Disease: AxatilimabPublished: February 21st 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk
2
Is Berberine Nature’s GLP-1?
3
Pharmacists Key to Counseling and Monitoring Patients Transitioning to Low-Sodium Oxybate
4
Incidence of VAIs in Patients With Chronic Kidney Disease on Dialysis Relatively Low
5
